The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
Paclitaxel (Taxol) and docetaxel (Taxotere) are among the most unique, and successful, chemotherapeutic agents used for the treatment of breast and ovarian cancer. Both agents have anti-mitotic properties derived from binding to tubulin and excessive stabilization of microtubules. Their anti-neoplastic effects derive from this mechanism. Distinct from their effects on microtubule stabilization, paclitaxel, docetaxel, and related taxanes display immunopharmacological traits. In this review, we discuss their induction of pro-inflammatory genes and proteins; the current hypotheses on the molecular mechanism for this induction, especially its relationship to the lipopolysaccharide (LPS) signaling pathway. We also discuss the structure-activity relationships (SAR) that govern gene induction, especially the striking differences between the SAR for murine and human cells in vitro. Lastly, we discuss the immunopharmacological traits of paclitaxel and docetaxel in terms of their relevance to human clinical pharmacology and toxicology and their activity in animal models of autoimmune disorders.
Fitzpatrick
F A
FA
Department of Oncological Science, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84103, USA. frank.fitzpatrick@hci.utah.edu
Wheeler
Richard
R
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy; D000077143:Docetaxel; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000276:immunology* / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D043823:Taxoids / Q000276:immunology* / Q000494:pharmacology*
D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel